Citadel Advisors
AMRI

Citadel Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

Citadel Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,500
Closed -$109K – 8800
2015
Q4 		$109K Sell
5,500
-26,400
-83% -$502K ﹤0.01% 6591
2015
Q3 		$556K Buy
31,900
+4,800
+18% +$97.7K ﹤0.01% 4658
2015
Q2 		$548K Buy
27,100
+20,200
+293% +$390K ﹤0.01% 4813
2015
Q1 		$121K Sell
6,900
-100
-1% -$1.7K ﹤0.01% 6688
2014
Q4 		$114K Sell
7,000
-12,700
-64% -$233K ﹤0.01% 6537
2014
Q3 		$435K Buy
19,700
+12,800
+186% +$262K ﹤0.01% 4804
2014
Q2 		$139K Buy
6,900
+6,800
+6,800% +$115K ﹤0.01% 5937
2014
Q1 		$2K Buy
+100
New +$1.38K ﹤0.01% 7742

Other funds holding AMRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Citadel Advisors's AMRI Position: Q2 2017 in Review

Citadel Advisors sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 137,557 shares — an estimated $1.93M sold.

Citadel Advisors first reported a position in AMRI in Q2 2013 and held it in 15 quarters. The position peaked at $2.13M in Q2 2013. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

  • Citadel Advisors reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
  • Citadel Advisors sold 137,557 Albany Molecular Research Inc shares in Q2 2017, an estimated $1.93M.
  • Citadel Advisors first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 15 quarters.
  • Citadel Advisors's Albany Molecular Research Inc position peaked at $2.13M in Q2 2013.
  • 136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Citadel Advisors's 13F filing for Q2 2017, filed 11 Aug 2017.